Introduction {#s1}
============

In the US, 45% of deaths can be attributed to fibrotic disorders including pulmonary fibrosis ([@B1]), for which a global rise in mortality is observed ([@B2]). This large and heterogeneous group of parenchymal lung disorders, termed interstitial lung disease (ILD) shares the common feature of pulmonary fibrosis resulting in impaired respiratory function and often failure. The most prevalent forms of ILD are idiopathic pulmonary fibrosis (IPF) and ILD associated with connective tissue diseases (CTD-ILD). CTDs commonly complicated by ILD include systemic sclerosis (SSc) ([@B3]), idiopathic inflammatory myopathies ([@B4]), rheumatoid arthritis ([@B5]), systemic lupus erythematous ([@B6]), Sjögren\'s syndrome ([@B7]), mixed connective tissue disease ([@B8]), and undifferentiated connective tissue disease ([@B9]). Among the different CTD-ILDs, ILD is most prevalent in SSc with 70--90% of SSc patients developing ILD ([@B10]). The life expectancy is markedly reduced, especially in IPF and SSc-ILD, with a median survival of 2--3 years from diagnosis ([@B2], [@B10]).

Despite their clinical heterogeneity, increasing data suggest that in ILD fibrosis develops due to the same dysregulation of wound-healing mechanisms ([@B11], [@B12]).Whereas cell death of alveolar epithelial cells is considered the key trigger of ILD ([@B13], [@B14]), a growing body of (pre-)clinical data point to a similarly crucial pathogenic role of pulmonary macrophages and macrophage-released factors ([@B15], [@B16]). Macrophage activation was shown throughout different stages of ILD including early/mild ([@B17]), intermediate ([@B18]) as well as end-stage/severe stages ([@B19]), and also in different ILD etiologies ([@B20]). These observations argue either for a persistent role of macrophages throughout the disease process or for the existence of "inflammatory" or "macrophage-driven" subtypes of ILD ([@B21], [@B22]). Importantly, the persistence of macrophages seems to correlate with poor prognosis and reduced overall survival ([@B17], [@B23]). Thus, the development of macrophage-targeted imaging techniques for prognostic and treatment purposes in ILD might represent a valuable approach to improve the deleterious disease outcome ([@B15]).

Molecular imaging, including nuclear imaging approaches such as positron emission tomography (PET) are sensitive and allow the non-invasive visualization of pathophysiologic processes in real-time. This is a unique advantage over conventional morphological imaging modalities such as high resolution computed tomography (HRCT) scans or magnetic resonance imaging (MRI) ([@B24]). These conventional imaging techniques depict anatomical changes in organ architecture with high spatial resolution. They can, however, neither provide information on whether the observed changes are signs of inactive or active tissue remodeling, nor discriminate inflammatory from fibrotic processes, a crucial information for informed clinical decision making ([@B12], [@B25]). An example is the presence of ground glass opacities, which commonly are considered to reflect alveolitis. However, the notion of alveolitis being synonymous to inflammation has been abandoned in fibrosing ILD, since early fibrotic interstitial changes have the same appearance on HRCT ([@B26]).

In recent years, several studies have investigated the potential of 2-deoxy-2-\[^18^F\]fluoro-D-glucose \[^18^F\]FDG-PET/CT for diagnosis of ILD. \[^18^F\]FDG is an unspecific, metabolic radiotracer for the assessment of cellular glucose metabolism, which has been shown to be elevated in ILD ([@B27], [@B28]). A disadvantage for its use in diagnosis and monitoring of ILD is that \[^18^F\]FDG signals reflect metabolic activity, which can arise from both inflammatory and fibrotic cell types and can occur during different disease stages including those of stabilization or repair. This lacking discrimination of pathophysiologic stages of ILD diminishes the value of \[^18^F\]FDG-PET/CT for informed treatment decisions and monitoring of therapeutic responses ([@B29], [@B30]).

In contrast, imaging approaches using target-specific radiotracers ideally aiming at a single key cell type in ILD may overcome this limitation of \[^18^F\]FDG-PET/CT. So far, only few approaches have been successfully applied pre-clinically in ILD ([@B31]--[@B36]).

Activated macrophages express folate receptor-β (FR-β) in various pathological conditions including cancer and inflammatory diseases ([@B37]--[@B39]), whereas the number of FR-β-expressing macrophages is very low under physiological conditions ([@B37], [@B40]).

FR-β is a glycosylphosphatidylinositol (GPI)-anchored protein, which binds folic acid and folate-linked molecules with high affinity and internalizes them via endocytosis. Imaging of FR-β can be realized with folate radiotracers. A number of folic acid-based radiotracers have been used pre-clinically for the imaging of activated macrophages in non-pulmonary, inflammatory conditions including e.g., rheumatoid arthritis, activated osteoarthritis, or atherosclerosis ([@B41]--[@B47]), FR-targeted radiopharmaceuticals have, however, not been evaluated yet in the context of ILD. Furthermore, the number of clinical studies making use of FR-targeting nuclear imaging strategies is limited including one exploratory trial in rheumatoid arthritis patients ([@B48]), since no folate-based radiotracer for PET imaging is currently available for clinical application.

A novel ^18^F-based folate PET radiotracer 3′-Aza-2′-\[^18^F\]-fluoro-folic acid, herein referred to as ^18^F-AzaFol), has recently been developed at the Center for Radiopharmaceutical Sciences ETH-PSI-USZ for FR imaging. The rationale to test this radiotracer instead of previously investigated macrophage imaging markers such as translocator protein (TSPO) was based on several disadvantages compared with ^18^F-AzaFol: TSPO (a) is mainly expressed in the outer mitochondrial membrane ([@B49]), thus it is not a cell surface receptor, (b) exhibits a high multicellular, basal expression in the lungs ([@B50]), and (c) TSPO-targeting PET tracers are still facing difficulties for clinical implementation. While the first generation of TSPO PET tracers showed high non-specific binding due to their lipophilic character ([@B51]), newer TSPO targeted radiotracers with improved binding specificity and affinity have still limitations due to the allelic dependency of the binding capability resulting from TSPO polymorphisms ([@B52]--[@B54]).

In this preclinical proof-of-concept study, we aimed to evaluate the potential of ^18^F-AzaFol-PET/CT for the specific visualization of macrophage-driven pathophysiologic processes in experimental ILD.

Methods {#s2}
=======

Human Subjects
--------------

Surgical lung biopsies from patients with IPF (*n* = 39) and CTD-ILD (*n* = 14), who underwent lung transplantation, were analyzed for the expression of FR-β. Lung sections from excess tissue from lung organ donors served as controls (*n* = 26). The patients\' characteristics including demographic and clinical data are summarized in the data supplement ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

The local ethics committee approved the study (BASEC-No. 2017-01298), and informed consent was obtained from all patients.

Murine Model of Bleomycin-Induced Lung Fibrosis
-----------------------------------------------

As a representative animal model for experimental ILD, we used the well-established mouse model of BLM-induced lung fibrosis in this study. In the BLM model, inflammation peaks around day 7, whereas fibrosis reaches its maximum between days 14-21 ([@B33], [@B35], [@B55]). M1-like macrophages dominate the early inflammatory phase, whereas M2-like macrophages are most abundant in the pro-fibrotic phase, although they might appear as early as day 7 ([@B56], [@B57]).

Female C57BL/6J-rj mice (5--7 weeks old) were purchased from Janvier (Le Genest-Saint-Isle, France) and housed at the institutional animal facilities under defined temperature, humidity, and light conditions, and received *ad libitum* a standard rodent diet. After an acclimatization period of at least 7 days, lung fibrosis was induced in 8-week-old mice by instilling intratracheally a single dose of bleomycin sulfate (4 U/kg of body weight, Baxter, cantonal pharmacy Zurich, Switzerland) dissolved in sterile saline solution under isoflurane anesthesia ([@B33]--[@B35]). Control mice received equivalent volumes of 0.9% NaCl (50 μl). At days 3, 7, and 14 after the BLM instillation, biodistribution, and imaging studies were performed. Perfused lungs of separate animals were harvested for immunostainings, histological, and molecular analyses.

All animal experiments performed in this study were approved by the cantonal veterinary offices and conducted in strict compliance with the Swiss animal welfare guidelines. For all experiments, mice were randomized into the different study groups in a non-blinded manner.

Histology
---------

For histology, perfused middle, caudal, and accessory lobes of the right mouse lung were inflated with 10% neutral-buffered formalin solution and fixed overnight at room temperature (RT). After embedding in paraffin, lung sections were cut at a thickness of 4 μm and stained with hematoxylin and eosin (HE) for analysis of the lung architecture and the presence of cellular infiltrates, and with Picrosirius Red to detect collagen deposition using standard protocols.

Immunohistochemistry on Murine Lung Tissues
-------------------------------------------

For immunohistochemistry (IHC) on murine tissues, lung sections were deparaffinized and rehydrated, and then subjected to heat-mediated antigen retrieval with 10 mM sodium citrate buffer (pH = 6.0) at 95°C for 15 min. After blocking of endogenous peroxidase activity with 3% hydrogen peroxide (15 min, RT), sections were blocked with 10% normal goat serum (1 h, RT) followed by blocking of endogenous biotin using an Avidin/Biotin blocking kit (Vector Laboratories, Burlingame, CA, United States). Afterwards, primary antibodies for F4/80 (rat anti-mouse F4/80, clone Cl:A3-1, 1:100, AbD Serotec; Kidlington, United Kingdom), and FR-β (rabbit anti-mouse FR-β, 1:400, Genetex, Irvine, CA, United States) were applied on the specimens and incubated overnight at 4°C. Isotype- and concentration-matched IgGs served as negative controls. Next, biotin-labeled goat anti-rat or anti-rabbit secondary antibodies (all from Vector Laboratories) were applied (30 min, RT). This was followed by incubation with the Vectastain ABC Elite HRP kit for 30 min at RT (Vector Laboratories). Finally, stainings were visualized using 3,3′-diaminobenzidine (DAB) in case of F4/80, or 3-amino-9-ethylcarbazole (AEC) (all from Vector Laboratories) in case of FR-β, and sections were counterstained with Mayer\'s hematoxylin (J.T. Baker, Deventer, Netherlands).

Immunohistochemistry on Human Lung Tissues
------------------------------------------

Immunohistochemistry was performed using an automated single-staining procedure (Benchmark Ultra; Ventana Medical Systems). Briefly, 4 μm thick sections were stained using mouse monoclonal anti-human antibodies directed against CD68 (clone PG-M1, Dako, 1:50) and FR-β (clone OTI8G1, Origen, 1:50). Detection was completed with respective secondary antibodies and the OptiView DAB Kit (Ventana Medical Systems).

Immunofluorescence
------------------

Immunofluorescence (IF) stainings were performed using the MaxDouble IF staining kits for rat and rabbit primary antibodies (MaxVision Biosciences Inc., Bothell, WA, United States). In brief, after blocking of auto-fluorescence for 5 min at RT, heat-mediated antigen retrieval with 10 mM sodium citrate buffer was performed for 15 min at 95°C. After antigen retrieval, primary antibodies for FR-β (rabbit anti-mouse FR-β, 1:800, Genetex), and F4/80 (rat anti-mouse F4/80, clone Cl:A3-1, 1:800, AbD Serotec), or concentration matched IgG isotype controls were applied and incubated overnight at 4°C. Next, specimens were incubated with rat and rabbit signal amplifier for 30 min at RT followed by washing and linkage to the respective fluorophores for 60 min at RT in the dark (anti-rat MaxFluor488 and anti-rabbit MaxFlour594). Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).

Microscopy and Image Analysis
-----------------------------

Histological and immunohistochemical stainings were recorded automatically with the AxioScan.Z1. slidescanner (Carl Zeiss, Feldbach, Switzerland) using a Plan-Apochromat 20×/0.8 M27 objective. For semi-quantitative expression analyses, per sample, six randomly selected high power fields were extracted with a 10× objective using the *Zen 2.0 lite* (blue edition) software. The percentage of positively stained pixels was automatically quantified using an in-house designed *MATLAB* script (Mathworks, *MATLAB* R2016b) to avoid observer bias. This script quantified the target-positive (= brown or red) pixels and cell nuclei-positive (= blue) pixels and calculated the percentage of positively stained pixels in relation to the total number of image pixels. To account for increased cell numbers and tissue consolidations, also the percentage of positively stained pixels in relation to the total number of colored image (brown or red + blue) pixels was calculated ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}).

For semi-quantitative assessment of murine and human lung fibrosis, the Ashcroft Score was applied on Picrosirius Red stained lung sections as described previously ([@B58]). Two blinded examiners performed the scorings in duplicates. If deviations of more than 1 score were observed, the respective slides were re-assessed to reach consensus.

Immunofluorescent pictures were recorded at 630× magnification (oil immersion) using the Olympus BX53 microscope in fluorescence mode (Olympus, Volketswil, Switzerland).

The total number of double positive (FR-β+/F4/80+) cells was quantified by both automated and manual image analyses using Orbit image analyses software version 3.15 (Objection Detection and Object Classification Module) ([@B59]) or manual counting by two blinded examiners, respectively.

RNA Extraction and Quantitative Reverse Transcription PCR
---------------------------------------------------------

For RNA extraction from mouse lungs, perfused cranial lobes were homogenized using the Qiagen TissueLyser and total RNA was isolated with the RNeasy Fibrous Tissue Mini Kit from Qiagen (Hombrechtikon, Switzerland). For quantitative reverse transcription PCR (RT-qPCR), 120 ng RNA were reverse-transcribed into complementary DNA with the Transcriptor First Strand cDNA Synthesis Kit from Roche (Basel, Switzerland) using anchored-oligo(dT)~18~ primer. Messenger RNA (mRNA) expressions were analyzed by SYBR Green qPCR on a Stratagene Mx3005P qPCR System (Agilent Technologies, Santa Clara, California, USA) using the SYBR Green GoTaq qPCR Master mix from Promega (Dübendorf, Switzerland) and specific primers for murine *Folr2* (forward primer: 5′-CCAGCAAGTGGACCAGAGTT-3′, reverse primer: 5′-CAGTCCCAGCCTTTATGCCA-3′; Microsynth, Balgach, Switzerland). As a housekeeping gene 60S acidic ribosomal protein P0 (*Rplp0;* forward primer: 5′-GCAGGTGTTTGACAACGGCAG-3′, reverse primer: 5′-GATGATGGAGTGTGGCACCGA-3; Microsynth) was used. The fold change of mRNA expression was calculated using the 2^−ΔΔ*Ct*^ method. False positive results due to primer dimers or genomic contamination were excluded by dissociation curve analysis and non-template controls, or by minus-reverse transcriptase controls, respectively.

Hydroxyproline Assay
--------------------

Collagen contents in lungs of BLM-treated mice and saline controls were quantified by hydroxyproline assay as described previously ([@B60]). Briefly, after homogenization, left lung lobes were digested in 6 M HCl for 3 h at 120°C and subsequently neutralized with 6 M NaOH. Next, samples were mixed with a 60 mM chloramine T solution and incubated for 20 min at RT. After addition of 3.15 M perchloric acid (5 min, RT), p-Dimethylaminobenzaldehyd (20% w/v) was added and samples were incubated for 20 min at 60°C. The absorbance was measured at 560 nm with a spectrophotometer (*GloMax-Multi Detection System*, Promega, Dübendorf, Switzerland).

Radiosynthesis of ^18^F-AzaFol
------------------------------

3′-Aza-2′-\[^18^F\]-fluoro-folic acid (^18^F-AzaFol) was produced on an automated synthesis module at the ETH Zurich (Switzerland) according to a previously reported method ([@B61]). ^18^F-AzaFol was applied at \~5 MBq (in 100 μL, 0.25--0.5 pmol/mouse) for biodistribution studies and at \~10 MBq (in 100 μL, 0.5--1 pmol/mouse) for *in vivo* and *ex vivo* PET/CT imaging. The *in vivo* stability of the tracer has been demonstrated in previous studies, in which only the intact parent radiotracer was detected. No downstream radiometabolites in blood plasma, urine, or liver samples were detectable ([@B61], [@B62]).

Biodistribution Studies
-----------------------

As an accurate means to quantify radiotracer uptake ([@B31]), biodistribution studies were performed. ^18^F-AzaFol was administrated via the lateral tail vein of mice. Receptor-blocking studies were performed by pre-injection of folinic acid (leucovorin; 300 nmol, 100 μL) \~30 min before the injection of ^18^F-AzaFol. Mice were sacrificed 1 h post injection (p.i.) of ^18^F-Azafol. Tissues and organs of interest were collected, weighed and counted for activity using a γ-counter (*Wallac Wizard 1480*, Perkin Elmer, Germany). The results were calculated as a percentage of the injected activity per gram of tissue mass (% IA/g) or expressed as a percentage of the injected activity per organ (% IA/organ). Thereafter, the already counted lungs were subjected to *ex vivo* PET/CT scans as described below.

*Ex vivo* and *in vivo* PET/CT Scans
------------------------------------

The *ex vivo* PET/CT scans of collected lungs (obtained from mice used for the biodistribution study) were performed using a small-animal bench-top PET/CT scanner (*G8*, Perkin Elmer, Massachusetts, USA; [Table 1](#T1){ref-type="table"}). Static PET scans of 20 min duration were acquired using the G8 acquisiton software (version 2.0.0.10) followed by CT scans of 1.5 min duration. The energy window ranged from 150 to 650 keV. The PET data were corrected for random coincidences, decay, and dead time and reconstructed with maximum-likelihood expectation maximization (MLEM). A correction for scatter was not made. The images were prepared using VivoQuant post-processing software (version 3.0, inviCRO Imaging Services and Software, Boston, USA). A Gauss post-reconstruction filter (FWHM = 1 mm) was applied to the PET images. The *ex vivo* PET/CT scans and biodistribution studies were performed in a separate experiment as the *in vivo* PET/CT scans. For *in vivo* imaging, static PET scans were performed 1 h p.i. of the radiotracer and lasted for 10 min followed by a CT of 1.5 min duration. During the *in vivo* PET/CT scans, the mice were anesthetized with a mixture of isoflurane and oxygen. The *in vivo* images were visualized using a dedicated 3D-rendering software (Ziostation2, Ziosoft, Tokyo, Japan).

###### 

Scan parameters for *in vivo* and *ex vivo* PET scans using *G8* bench-top PET/CT scanner.

  -------------------------------------- --------------
  Energy window                          150--650 keV
  Isotope                                Fluorine 18
  Framing sequence                       Static
  Duration of static PET scans           
      *In vivo* (chest region)           10 min
      *Ex vivo* (isolated whole lungs)   20 min
  Normalization                          Yes
  Dead time correction                   Yes
  Decay correction                       Yes
  Scatter correction                     No
  Image reconstruction                   
       Number of iterations              60
  Attenuation correction                 Yes
  -------------------------------------- --------------

*In vivo and ex vivo scans were performed 1 h after the injection of ^18^F-AzaFol (\~10 MBq in 100 μL, 0.5--1 pmol/per mouse)*.

For both, biodistribution studies/*ex vivo* scans and the *in vivo* scans per each time point the following numbers of mice have been used: *n* = 3--4 for saline-treated mice, *n* = 3--4 for BLM-treated mice and *n* = 2--4 for BLM-treated mice receiving leucovorin for FR blockade.

Statistics
----------

Statistical analysis was performed using GraphPad Prism 7 software (version 7.04). Unless otherwise indicated, non-parametric data were expressed as median ± interquartile range (IQR) and parametric data were expressed as mean ± standard deviation (S.D.). For non-parametric non-related data, the Mann--Whitney *U*-test for comparison of two groups, or the Kruskal--Wallis test followed by Dunn\'s multiple correction for comparison of multiple groups was employed. For parametric non-related data, an unpaired *t*-test was applied for comparison between two groups, or a One-Way ANOVA with Tukey\'s *post-hoc* test for comparison between multiple groups was performed. For correlation analysis, Spearman rank correlation was performed. *P*-values \< 0.05 were considered statistically significant.

Results {#s3}
=======

FR-β Expression Is Upregulated in Human ILD and Correlates With Disease Severity
--------------------------------------------------------------------------------

To assess the presence of FR-β-positive macrophages in human ILD, we performed IHC for FR-β on lung explants derived from patients with IPF (*n* = 39) and CTD-ILD (*n* = 14), who underwent lung transplantation. Lung sections from excess tissue from lung organ donors served as controls (*n* = 26) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

As anticipated, the histopathological analysis of lung tissues from both patients with IPF and CTD-ILD revealed severe damage of the normal tissue architecture with increased numbers of mononuclear inflammatory infiltrates and excessive interstitial collagen deposition as assessed by HE or Picrosirius Red staining ([Figure 1A](#F1){ref-type="fig"}), respectively. This was also reflected in the semi-quantitative Ashcroft score of pulmonary fibrosis with a median score of 6.125 (Q1, Q3 = 5.625, 6.5; *p* \< 0.0001) for IPF and a median score of 5 (Q1, Q3 = 4.219, 6.531; *p* \< 0.0001) for CTD-ILD patients ([Figure 1B](#F1){ref-type="fig"}). In most cases, lung remodeling in IPF and CTD-ILD patients had histological features of usual interstitial pneumonia (UIP) characterized by patchy fibrosis and areas of honeycombing, whereas only the minority of patients displayed patterns of non-specific interstitial pneumonia (NSIP), characterized by a more uniformly spread fibrosis and better preserved lung architecture ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). In these highly inflammatory and fibrotic lung sections, presence of FR-β was significantly increased ([Figure 1A](#F1){ref-type="fig"}) with median increases of \~ 3- to 4-fold in both IPF and CTD-ILD patients ([Figure 1C](#F1){ref-type="fig"}, [Supplementary Figure 2A](#SM1){ref-type="supplementary-material"}; *p* \< 0.0001). To confirm the expression of FR-β on macrophages ([@B40], [@B63]), we additionally performed IHC for CD68, a human pan-macrophage marker, on sequential lung sections from healthy controls, IPF and CTD-ILD patients. In accordance with the increased FR-β expression, we also found increased CD68 expression in lung sections from both IPF and CTD-ILD patients with median increases of 1.69-fold (Q1, Q3 = 1.37, 2.29; *p* \< 0.0001) and 1.89-fold (Q1, Q3 = 1.09, 2.8; *p* \< 0.01), respectively ([Figure 1D](#F1){ref-type="fig"}, [Supplementary Figure 2B](#SM1){ref-type="supplementary-material"}). Consistently, FR-β expression also strongly correlated with the CD68 expression (*r* = 0.70, *p* \< 0.0001; [Figure 1E](#F1){ref-type="fig"}). Whereas, a strong expression of CD68 was observed on macrophages in the alveolar spaces, FR-β was mostly expressed in the lung interstitium ([Figure 2](#F2){ref-type="fig"}). Furthermore, while the upregulation of CD68 and FR-β in IPF and CTD-ILD patients was independent of the histological subtype ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}), the expression of FR-β significantly increased with the severity of lung remodeling ([Figure 1F](#F1){ref-type="fig"}) and positively correlated with the Ashcroft score as measure of lung remodeling (*r* = 0.84, *p* \< 0.0001; [Figure 1G](#F1){ref-type="fig"}).

![FR-β expression is increased in human ILD and correlates with the severity of lung remodeling. **(A)** Representative images of lung sections from healthy controls (HC) and patients with IPF and CTD-ILD stained with hematoxylin and eosin (HE, first panel), Picrosirius Red (collagen = red, second panel), FR-β (brown, third panel) and CD68 (brown, fourth panel). Representative pictures at 100× magnification (scale bars: 100 μm) and at higher magnification (400×, scale bars: 20 μm) are shown. **(B)** Semi-quantification of pulmonary fibrosis by Ashcroft score. **(C)** Semi-quantification of FR-β tissue expression by automatic image analysis. **(D)** Semi-quantification of CD68 tissue expression by automatic image analysis. **(E)** Spearman correlation of FR-β expression with the CD68 expression. **(F)** Analysis of FR-β expression according to the severity of lung remodeling as defined by the Ashcroft score (score 0--1: no fibrosis, scores \>1--3: mild fibrosis, scores \>3--5: moderate fibrosis, scores \>5--8: severe fibrosis). **(G)** Spearman correlation of FR-β expression with the Ashcroft score. For **(B--D,F)** data are displayed as box plots with min/max values. For statistical analysis, the Kruskal--Wallis test with Dunn\'s multiple correction was applied (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001). For all experiments: *n* = 26 for healthy controls, *n* = 39 for IPF patients, and *n* = 14 for CTD-ILD patients.](fimmu-10-02724-g0001){#F1}

![FR-β is mostly expressed in the lung interstitium in human ILD. Representative images of sequential lung sections from healthy controls (HC, *n* = 26) and patients with IPF (*n* = 39) and CTD-ILD (*n* = 14) that were stained with FR-β and the human macrophage marker CD68. **(A)** Overview images at 100× magnification are shown (scale bars: 100 μm). Colored squares indicate regions of interest for the higher magnification images depicted in **(B,C)**. **(B)** Higher magnification images at 400× magnification (scale bars: 20 μm) indicating the only weak to undetectable expression of FR-β on macrophages located in alveolar spaces (arrows). **(C)** Higher magnification images at 400× magnification (scale bars: 20 μm) indicating the strong expression of FR-β on macrophages located in the lung interstitium.](fimmu-10-02724-g0002){#F2}

FR-β Expression Is Also Upregulated in Experimental ILD and Changes With Disease Development
--------------------------------------------------------------------------------------------

Next, we assessed whether the expression of FR-β was mirrored in a representative mouse model of human ILD, the BLM-induced lung fibrosis model.

Upon a single intratracheal BLM administration, mice progressively developed lung remodeling with inflammation (days 3--7) preceding the development of pulmonary fibrosis (day 14). As early as day 3, the histopathological examination of lung sections from BLM-treated mice vs. saline controls revealed the presence of mononuclear cell infiltrates ([Figure 3A](#F3){ref-type="fig"}) around the vessels and bronchi with increased numbers of macrophages as assessed by IHC with the murine macrophage marker F4/80 ([Figure 3B](#F3){ref-type="fig"}). In contrast, only minimal fibrous thickening of the alveolar and bronchial walls ([Figure 3C](#F3){ref-type="fig"}) was detected, which was also reflected by a low median Ashcroft score of 2.5 (Q1, Q3 = 2, 3; *p* \< 0.01; [Figure 3D](#F3){ref-type="fig"}). With disease progression, the number of macrophages increased in BLM-treated lungs and peaked at day 7 with a median 4.11-fold increase (Q1, Q3 = 2.38, 10.65; *p* \< 0.001; [Figure 3E](#F3){ref-type="fig"}, [Supplementary Figure 2D](#SM1){ref-type="supplementary-material"}) and subsided thereafter. Consistently, pulmonary fibrosis gradually increased with extensive interstitial collagen deposition characterized by the formation of fibrous bands and larger fibrous masses in subpleural as well as perivascular and peribronchial areas ([Figure 3C](#F3){ref-type="fig"}). Maximally established fibrosis was detected at day 14 as demonstrated by a high median Ashcroft score of 5 (Q1, Q3 = 4.25, 5.5; *p* \< 0.001). The lung collagen content as assessed by hydroxyproline (HP) assay increased over time in BLM-treated mice with a median 1.32-fold (Q1, Q3 = 1.17, 1.42; *p* \< 0.05) increase at day 14 ([Figure 3F](#F3){ref-type="fig"}).

![Intratracheal instillation of bleomycin in mice induces progressive lung remodeling characterized by increased numbers of macrophages. **(A)** Representative images of lung sections from saline-treated controls and BLM-treated mice at days 3, 7, and 14 stained with hematoxylin and eosin (HE), **(B)** the murine macrophage marker F4/80 (brown), and **(C)** Picrosirius Red (collagen = red). **(D)** Semi-quantitative assessment of lung fibrosis by Ashcroft score. **(E)** Semi-quantification of pulmonary macrophages by automatic image analysis of F4/80 expression. **(F)** Quantification of left lung collagen content by hydroxyproline (HP) assay. For **(A--C)** representative pictures at 100× magnification (scale bars: 100 μm) and at higher magnification (400×, scale bars: 20 μm) are shown. For **(D--F)** data are presented as medians ± IQR. For statistical analysis, the Mann--Whitney U-test was applied (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001). For all experiments: *n* = 4--6 for saline controls and *n* = 6--10 for BLM-treated mice.](fimmu-10-02724-g0003){#F3}

In accordance with the expression in human ILD and the time course of the appearance of pulmonary macrophages in this animal model, FR-β expression significantly increased over time in lungs of BLM-treated mice ([Figure 4A](#F4){ref-type="fig"}). While FR-β was only weakly expressed in the lungs of saline-treated controls, FR-β expression was significantly upregulated in lungs of BLM-treated mice with peak at day 3 at the mRNA level ([Figure 4B](#F4){ref-type="fig"}) and at day 7 at the protein level ([Figures 4A,C](#F4){ref-type="fig"}, [Supplementary Figure 2C](#SM1){ref-type="supplementary-material"}) and thus in the inflammatory phase in this animal model with a median increase of 1.98-fold (Q1, Q3 = 1.61, 2.19; *p* \< 0.001) and 4.41-fold (Q1, Q3 = 2.4, 6.83; *p* \< 0.01), respectively. The expression of FR-β on murine lung macrophages was confirmed by immunofluorescent double staining using an antibody for murine macrophages, F4/80 ([Figure 4D](#F4){ref-type="fig"}, [Supplementary Figure 4](#SM1){ref-type="supplementary-material"}).

![FR-β expression is increased in experimental ILD and correlates with the severity of lung remodeling. **(A)** Representative images of lung sections from saline-treated controls and BLM-treated mice at days 3, 7, and 14 stained for FR-β (red). Representative pictures at 100× magnification (scale bars: 100 μm) and at higher magnification (400×, scale bars: 20 μm) are shown. **(B)** Fold change of mRNA expression of *Folr2* in BLM-treated mice vs. saline-treated controls at days 3, 7, and 14. **(C)** Semi-quantification of FR-β tissue expression by automatic image analysis. **(D)** Representative images of immunofluorescent double staining of FR-β (red) with the murine macrophage marker F4/80 (green) performed on lung sections from saline-treated controls and BLM-treated mice at day 7. For **(D)** representative images from three mice each at 630× magnification are shown (scale bars: 10 μm). **(E)** Spearman correlation of FR-β expression with the Ashcroft score. **(F)** Analysis of FR-β expression according to the severity of lung remodeling as defined by the Ashcroft score (score 0--1: no fibrosis, scores \>1--3: mild fibrosis, scores \>3--5: moderate fibrosis, scores \>5--8: severe fibrosis). For **(B,C,F)** data are presented as medians ± IQR. For statistical analysis the Kruskal--Wallis test with Dunn\'s multiple correction or the Mann--Whitney *U*-test was applied (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001). For all experiments: *n* = 6 for saline-treated controls, *n* = 9--10 for BLM-treated mice.](fimmu-10-02724-g0004){#F4}

As in human ILD patients, the expression of FR-β also positively correlated with the Ashcroft score (*r* = 0.64, *p* \< 0.0001; [Figure 4E](#F4){ref-type="fig"}) and, hence, with the degree of lung remodeling ([Figure 4F](#F4){ref-type="fig"}).

Pulmonary Accumulation of ^18^F-AzaFol, a Surrogate Marker for FR-β-Positive Macrophages, Reflects Macrophage-Related Disease Development in Experimental ILD
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Having established the time course of FR-β expression in this mouse model, we next performed nuclear imaging experiments to assess whether macrophage-related disease development could be visualized by ^18^F-AzaFol.

In strong correlation with the expression changes of FR-β at the tissue level, BLM-treated mice showed increased pulmonary accumulation of ^18^F-AzaFol from days 3 to 14, as assessed by *ex vivo* biodistribution studies at 1 h p.i. of ^18^F-AzaFol ([Figures 5A,B](#F5){ref-type="fig"}). The maximum lung accumulation was observed at day 7 with a mean total uptake of 1.01 ± 0.30% injected activity per lung (% IA/lung) and 3.33 ± 0.77% injected activity per tissue mass (% IA/g) in BLM-treated vs. control animals (0.31 ± 0.06% IA/lung and 1.78 ± 0.15% IA/g; *p* \< 0.01 and *p* \< 0.05, respectively). The specificity of the pulmonary tissue uptake of ^18^F-AzaFol was validated by receptor blockade using folinic acid (leucovorin) administrated to mice 30 min prior to the injection of the radiotracer. This significantly reduced the lung accumulation of ^18^F-AzaFol in BLM-treated mice, resulting in pulmonary radioactivity accumulation comparable to saline-treated controls. *Ex vivo* PET/CT scans of isolated lungs also clearly distinguished diseased from healthy lungs and confirmed the successful receptor blockade ([Figure 5C](#F5){ref-type="fig"}). *In vivo* PET/CT scans of the chest region of the animal showed a generally low pulmonary accumulation of ^18^F-AzaFol with background signals in bone and muscles in both NaCl-treated controls and BLM-treated mice. A slightly increased signal intensity compared with control mice was observed in lungs of BLM-treated mice at the maximum of inflammation at day 7 ([Supplementary Figure 5](#SM1){ref-type="supplementary-material"}).

![Pulmonary accumulation of ^18^F-AzaFol reflects macrophage-related disease development in experimental ILD. **(A)** *Ex vivo* lung uptake of ^18^F-AzaFol (1 h p.i.) shown as percentage of injected activity per lung (% IA/lung) or **(B)** shown as percentage of injected activity per lung mass (% IA/g) in lungs from saline-treated controls and BLM-treated mice with and without receptor blockade at days 3, 7, and 14. **(C)** *Ex vivo* PET/CT scans of lungs from saline controls and BLM-treated mice with and without receptor blockade at days 3, 7, and 14 that were collected 1 h after injection of ^18^F-AzaFol. Scans are shown as maximum intensity projections. **(D)** Representative tissue distribution of ^18^F-AzaFol (1 h p.i.) in organs of interest of saline-treated controls and BLM-treated mice. Biodistribution data are shown for day 7, when the strongest pulmonary accumulation of ^18^F-AzaFol was observed. Data are expressed as percentage of injected activity per gram of tissue (% IA/g). For **(A,B,D)** data are presented as means ± S.D. For statistical analysis, the One Way ANOVA test with Tukey\'s multiple correction was applied (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, vs. saline; ^\#^*p* \< 0.05, ^*\#\#*^*p* \< 0.01, ^*\#\#\#*^*p* \< 0.001, vs. BLM). For all experiments: *n* = 3--4 for saline-treated controls, *n* = 3--4 for BLM-treated mice, and *n* = 2--4 for BLM-treated mice receiving receptor blockade.](fimmu-10-02724-g0005){#F5}

The distribution of ^18^F-AzaFol in other organs besides the lungs was comparable between BLM-treated mice and saline-treated control animals at day 7 ([Figure 5D](#F5){ref-type="fig"}, [Supplementary Tables 2](#SM1){ref-type="supplementary-material"}, [3](#SM1){ref-type="supplementary-material"}). The slightly increased uptake in both experimental groups in lymphoid organs (e.g., thymus, lymph nodes), which may have been also affected by the BLM treatment ([@B64]), is most likely caused by the presence of activated macrophages expressing FR--β ([@B65], [@B66]), a phenomenon, previously observed in lymph nodes of tumor-bearing mice ([@B61]). The high basal liver uptake of ^18^F-AzaFol observed in both controls and BLM-treated mice can be explained by the fact that folate vitamins are physiologically stored in the liver. Since ^18^F-AzaFol is not a conjugate of folic acid, as this is the case with other folate radioligands, ^18^F-AzaFol may also be transported through carrier systems such as the proton-coupled folate transporter. A relatively high liver uptake and potential signs of metabolism were also shown in our previous studies, in which we evaluated ^18^F-AzaFol for the first time ([@B61]).

The distinct drop in activity after treatment with the FR blocking agent in both liver and lymph nodes further argues for a folate-specific effect rather than an unspecific accumulation mechanism.

Discussion {#s4}
==========

In different types of ILD, an increased lung uptake of \[^18^F\]FDG was observed in pathologically changed areas of reticulation/honeycombing and ground-glass opacities, but also in radiologically normal-appearing lung areas ([@B28], [@B29], [@B67]--[@B71]). \[^18^F\]FDG uptake, especially in normal appearing lung parenchyma, was shown to be of prognostic value and to correlate with overall disease severity in IPF patients ([@B28], [@B68], [@B70]). However, \[^18^F\]FDG-PET/CT has also important limitations for the diagnosis and monitoring of ILD since it visualizes changes in glucose metabolism in a non-specific, cell-type-independent manner ([@B25], [@B26], [@B67]), and does not allow to draw conclusions on the pathophysiological disease stage ([@B30], [@B72]). In our study, ^18^F-AzaFol visualized macrophage-related ILD development in the mouse model of BLM-induced lung fibrosis in *ex vivo* PET/CT scans and tissue expression of FR-β showed good correlation with the pulmonary radiotracer uptake in the biodistribution studies. This has important clinical implications.

As ILDs are highly heterogeneous on molecular level, such a targeted molecular imaging approach could be used in the future for a molecular stratification of ILD patients, i.e., the identification of subgroups of patients, who are likely to benefit from macrophage-oriented therapies and who will be eligible for subsequent monitoring of therapeutic responses. This is of particular interest due to the recent or imminent approval of such therapies for ILD ([@B73]--[@B75]). These include pirfenidone and nintedanib, which have pre-clinically shown to exert their anti-fibrotic effects at least partially by targeting pulmonary macrophages and/or their products ([@B75]--[@B77]) as well as tocilizumab, which was assessed in recent phase II and III randomized controlled studies ([@B78]). In addition, the ability to identify ILD patients based on their underlying molecular and cellular subtype without the need of lung biopsies might also have relevance for clinical trial design by allowing the definition of (more) homogenous patients\' subgroups and by serving as a primary/secondary readout for macrophage-orientated treatment studies. To this end, additional preclinical studies to confirm the suitability for ^18^F-AzaFol for predicting and monitoring therapeutic efficacy will have to be performed. The alterations of tissue uptake of ^18^F-AzaFol throughout the development of experimental ILD were in strong accordance with the time course of macrophage presence on tissue level, which documents a good sensitivity to change. This quality is an important prerequisite for the monitoring of macrophage-targeted treatment responses, which we have not yet tested pre-clinically.

Another important finding of this study was that the numbers of (FR-β-positive) macrophages were substantially increased in human ILD patients, irrespective of the underlying etiology. This observation has some interesting implications. Firstly, it supports the re-evaluation of the pathophysiology of fibrotic ILD as immune-mediated and thus, as potentially amenable to immune-targeted therapies ([@B12]). Secondly, the persistence of macrophages throughout different stages of experimental ILD and their presence in late disease stages in the human disease points to an important role in the whole process of tissue remodeling ([@B79]). Thus, the characterization of macrophage subpopulations, particularly of FR-β-positive macrophages, might further elucidate the mechanisms of fibrosis in ILD and identify novel macrophage- or macrophage-related therapeutic targets ([@B15]) including FR-β-targeted molecular therapies ([@B40], [@B80]--[@B82]).

The exploratory character of our study accounts for some of its limitations. The model of BLM-induced lung fibrosis, although extensively used and widely acknowledged as a valuable model of experimental ILD, does not reflect the chronic disease course in human patients, since following the single instillation of BLM, fibrosis gradually resolves over 4--8 weeks ([@B55]). Furthermore, the imaging analyses have been limited to the stages of active disease and later time points of resolution of fibrosis (days 21--28) have not been investigated. For pathophysiologic studies to elucidate the whole process of macrophage-related tissue remodeling in ILD in detail, FR-β-targeted nuclear imaging would have to be performed (a) in the phase of tissue repair in the acute BLM model and (b) in non-resolving, chronic disease models of ILD ([@B83]). Numerous studies, however, are now focusing on the acute, pro-inflammatory phase and the role of macrophages in fibrosis development in this model ([@B15], [@B56], [@B57]), which support the importance and comparability of its early stages to certain aspects of human ILD.

Another important limitation of our proof-of-concept study is that our nuclear imaging experiments are largely based on *ex vivo* analyses and quantifications. Furthermore, the performance of static PET scans did not allow the correction for changes in pulmonary blood flow. Elevated blood flow and increased vascular leakage are cardinal features of lung inflammation and fibrosis ([@B34], [@B84]). These phenomena could have contributed non-specifically to the pulmonary accumulation of ^18^F-AzaFol in BLM-treated mice. The fact that receptor blockade with folinic acid lowered the radiotracer uptake to the level of control mice, however, points to a receptor-specific rather than a non-specific pulmonary uptake of ^18^F-AzaFol.

In future preclinical experiments to further support the specificity of ^18^F-AzaFol-PET/CT, (a) the quality of the *in vivo* imaging should be improved by using gated respiration during the acquisition of the nuclear images to reduce motion artifacts, which could affect tissue density, (b) dynamic PET scans should be performed to account for blood flow-related changes, and (c) signal intensities should be also quantified *in vivo* e.g., by calculating the standardized uptake values ([@B84], [@B85]). These additional studies would allow to better estimate the clinical applicability of ^18^F-AzaFol-PET/CT. For the extrapolation of our preclinical data to humans, it is further important to note that the endogenous folate levels largely differ between rodents and humans (\~15--40 fold higher in mice). In our study, this could have led to an underestimation of the actual ^18^F-AzaFol tissue uptake since endogenous folate might also compete with ^18^F-AzaFol for binding to the FR ([@B86]).

In general, the transferability of results from animal models, which, even though representative of certain aspects, never cover the whole complexity of a human disease, is always a matter of debate. However, previous studies using the murine BLM-induced lung fibrosis model provided evidence for its suitability for both imaging ([@B33], [@B87]) and molecular analyses ([@B88]) and our own data showed similarly high pulmonary expression levels of FR-β in experimental and (end-stage) human ILD.

In conclusion, our proof-of-concept study showed that nuclear imaging using ^18^F-AzaFol can visualize macrophage-related experimental ILD. The fact that FR-β---apart from being a cellular rather than a metabolic marker---is only expressed on activated macrophages in disease states such as inflammatory disorders or malignancies, supports ^18^F-AzaFol as a more specific alternative to \[^18^F\]FDG in ILD. Since ^18^F-AzaFol-PET/CT has been tested for targeting FR-positive tumors in a Swiss multi-center trial (NCT03242993; [www.clinicaltrials.gov](http://www.clinicaltrials.gov)), its clinical availability, including first-in-human clinical trials for imaging of ILD, is impending.
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ILD

:   Interstitial lung disease

PET/CT

:   Positron emission computed tomography/computed tomography

BLM

:   Bleomycin

IPF

:   Idiopathic pulmonary fibrosis

CTD-ILD

:   Connective tissue disease-associated interstitial lung disease

SSc

:   Systemic sclerosis

HRCT

:   High resolution computed tomography

MRI

:   Magnetic resonance imaging

\[^18^F\]FDG

:   \[^18^F\]fluorodeoxyglucose

FR-β

:   Folate receptor-β

GPI

:   Glycosylphosphatidylinositol

^18^F-AzaFol

:   3′-Aza-2′-\[^18^F\]-fluoro-folic acid

RT

:   Room temperature

HE

:   Hematoxylin and eosin

IHC

:   Immunohistochemistry

DAB

:   Diaminobenzidine

AEC

:   3-Amino-9-ethylcarbazole

IF

:   Immunofluorescence

DAPI, 4′

:   6-Diamidino-2-phenylindole

RT-qPCR

:   Quantitative reverse transcription polymerase chain reaction

mRNA

:   Messenger RNA

Rplp0

:   60S acidic ribosomal protein P0

p.i.

:   Post injection

\% IA/g

:   Percentage of the injected activity per gram of tissue mass

\% IA/organ

:   Percentage of the injected activity per organ

MLEM, Maximum-likelihood expectation maximization IQR

:   Interquartile range

S.D.

:   Standard deviation

UIP

:   Usual interstitial pneumonia

NSIP

:   Non-specific interstitial pneumonia

HP

:   Hydroxyproline.
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